Latest News
Nov 14, 2017
ReViral present at OneNucleus

Reviral's Chief Operating Officer, Rachel Harland, will be delivering a presentation at Chesterford Research Park on the 15th of November as part of the OneNucleus Leadership Seminar entitled - "Addressing...

Nov 10, 2017
ReViral at Pharma Integrates 2017

ReViral’s CEO, Eddy Littler, will be a panellist at Pharma Integrates 2017 (Biotech CEO Panel Series: Crossing the Valley of Death Between Discovery and Proof of Concept). For more information, see the

Nov 2, 2017
ReViral present Phase 2a update at BIO-Europe

ReViral’s CEO, Eddy Littler, will be presenting an update on their Phase 2a clinical proof of concept study for Respiratory Syncytial Virus on Tuesday November 7th at BIO-Europe partnering meeting. He will be...

Sep 5, 2017
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus

Challenge trial will evaluate RV521 in approximately 70 volunteers

London, UK, 5th September 2017 - ReViral, a UK-based biotech company focused on developing novel...

Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers

Phase 2a RSV Challenge Study Planned for Q3 2017

London, UK, 24th April 2017 - ReViral, a UK based biotechnology company focused on the discovery and development...

Oct 31, 2016
ReViral initiates Phase 1 clinical trial of potent oral inhibitor against Respiratory Syncytial Virus

London, UK, 31st October 2016 - ReViral, an antiviral drug discovery and development company developing innovative therapies against Respiratory Syncytial Virus (RSV), announced today...

Archived News
Mar 9, 2017
Iain Dukes joins the ReViral Board
Oct 3, 2016
ReViral Announces Appointment of New Chief Executive Officer
Jun 17, 2016
New laboratory facilities for ReViral
Jun 17, 2016
ReViral Relocates
Mar 30, 2016
ReViral Scientific Advisory Board meeting
Jan 1, 2016
Dr Elaine Thomas joins the ReViral team as Head of Virology
Dec 1, 2015
ReViral – Opens new London Office
Nov 4, 2015
ReViral are delighted to announce the appointment of Dr Rachel Harland to the post of COO in the company’s management team
Oct 6, 2015
ReViral is recruiting
Sep 8, 2015
ReViral announces US$21 million fundraising to advance clinical development of a novel anti-viral drug
Dec 2, 2014
ReViral Receives over US$1Mn in Funding
Oct 31, 2014
ReViral Ltd Appoints Max Herrmann as Chief Financial Officer
Apr 15, 2014
Professor Raymond Schinazi joins Board of ReViral as Non-executive Director
Dec 6, 2013
ReViral has been granted a Seeding Drug Discovery award from the Wellcome Trust to develop novel small molecule RSV fusion inhibitors
Jul 10, 2012
ReViral Project Shortlisted for Wellcome Trust SDDI Award
Upcoming Events
10th Annual Biotech Showcase
Jan 8, 2018 to Jan 11, 2018
San Francisco
More Information
Past Events
BioEurope Partnering Conference
Mar 19, 2017 to Mar 22, 2017
Barcelona
More Information
Bio International Convention
Jun 19, 2017 to Jun 22, 2017
Berlin
More Information
Bio Europe
Nov 6, 2017 to Nov 8, 2017
Berlin
More Information